These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685 [TBL] [Abstract][Full Text] [Related]
4. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Kratochwil C; Giesel FL; López-Benítez R; Schimpfky N; Kunze K; Eisenhut M; Kauczor HU; Haberkorn U Clin Cancer Res; 2010 May; 16(10):2899-905. PubMed ID: 20460485 [TBL] [Abstract][Full Text] [Related]
5. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Wulfert S; Kratochwil C; Choyke PL; Afshar-Oromieh A; Mier W; Kauczor HU; Schenk JP; Haberkorn U; Giesel FL Mol Imaging Biol; 2014 Aug; 16(4):586-94. PubMed ID: 24526358 [TBL] [Abstract][Full Text] [Related]
6. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778 [TBL] [Abstract][Full Text] [Related]
7. Multimodal Imaging of 2-Cycle PRRT with Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703 [TBL] [Abstract][Full Text] [Related]
8. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Stoeltzing O; Loss M; Huber E; Gross V; Eilles C; Mueller-Brand J; Schlitt HJ Langenbecks Arch Surg; 2010 Feb; 395(2):185-92. PubMed ID: 19506898 [TBL] [Abstract][Full Text] [Related]
9. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Giesel FL; Kratochwil C; Mehndiratta A; Wulfert S; Moltz JH; Zechmann CM; Kauczor HU; Haberkorn U; Ley S Eur J Radiol; 2012 Oct; 81(10):2820-5. PubMed ID: 22236704 [TBL] [Abstract][Full Text] [Related]
10. Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC. Cieciera M; Kratochwil C; Moltz J; Kauczor HU; Holland Letz T; Choyke P; Mier W; Haberkorn U; Giesel FL Diagn Interv Radiol; 2016; 22(3):201-6. PubMed ID: 27015320 [TBL] [Abstract][Full Text] [Related]
11. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582 [TBL] [Abstract][Full Text] [Related]
12. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064 [TBL] [Abstract][Full Text] [Related]
14. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with Weikert T; Maas OC; Haas T; Klarhöfer M; Bremerich J; Forrer F; Sauter AW; Sommer G Contrast Media Mol Imaging; 2019; 2019():1517208. PubMed ID: 31787860 [TBL] [Abstract][Full Text] [Related]
15. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors. Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409 [TBL] [Abstract][Full Text] [Related]
16. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors. Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056 [TBL] [Abstract][Full Text] [Related]
17. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441 [TBL] [Abstract][Full Text] [Related]
18. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971 [TBL] [Abstract][Full Text] [Related]